In this episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock catches up with Adityo Prakash, CEO of Verseon, to shed some light on what the potential of AI in drug discovery
Alphabet subsidiary and precision health company Verily recently announced a breakthrough in its AI drug discovery GPCR research collaboration with Sosei Heptares.
Sanofi is tapping San Francisco-based Atomwise for a new AI-fuelled drug discovery deal, paying $20 million for five new drug targets — and possibly spending more than a billion in mileston
AI could address the most significant issue in drug discovery, finds Ben Hargreaves, and also offers the potential to use tissue samples to create precision medicine for specific patient gr
As the ASCO congress drew to a close, Johnson & Johnson filed for FDA approval of its BCMA-targeting CAR-T therapy Carvykti for use earlier in the treatment pathway fo
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas
